170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study

Autor:	W. Wick, A. IdBaih, M. Vieito Villar, G. Tabatabai, A. Stradella, F. Ghiringhelli, M. Burger, I. Mildenberger, U. Herrlinger, M. Touat, P. Wen, A. Wick, C. Gouttefangeas, A. Maia, C. Bonny, J-M. Paillarse, J. Fagerberg, D.A. Reardon
Rok vydání:	2022
Předmět:	Oncology Immunology and Allergy
Zdroj:	Immuno-Oncology and Technology. 16:100282
ISSN:	2590-0188
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c5893d68a11809371fd9a6eec3ca21d1 https://doi.org/10.1016/j.iotech.2022.100282 Zobrazit plný text záznamu